Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:public_company
|
| gptkbp:CEO |
gptkb:Paul_McKenzie
|
| gptkbp:country |
gptkb:Australia
|
| gptkbp:foundedYear |
1916
|
| gptkbp:founder |
gptkb:Government_of_India
|
| gptkbp:headquartersLocation |
gptkb:Melbourne,_Australia
|
| https://www.w3.org/2000/01/rdf-schema#label |
ASX: CSL
|
| gptkbp:industry |
gptkb:biotechnology
pharmaceuticals |
| gptkbp:ISIN |
gptkb:AU000000CSL8
|
| gptkbp:marketCap |
over AUD 100 billion (as of 2023)
|
| gptkbp:name |
gptkb:CSL_Limited
|
| gptkbp:numberOfEmployees |
over 30,000 (2023)
|
| gptkbp:products |
vaccines
plasma-derived therapies recombinant proteins |
| gptkbp:stockExchange |
gptkb:Australian_Securities_Exchange
|
| gptkbp:stockSymbol |
gptkb:CSL
|
| gptkbp:subsidiary |
gptkb:CSL_Behring
gptkb:Seqirus |
| gptkbp:website |
https://www.csl.com/
|
| gptkbp:bfsParent |
gptkb:Commonwealth_Serum_Laboratories
|
| gptkbp:bfsLayer |
6
|